Programs & products

Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer Trial conducted in Europe and the United States Innate Pharma SA (the...

Proprietary, new cytotoxic anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL); Orphan drug designation in the European Union; Innate’s third first-in...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced that it has received a US$5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licencing...

Third trial opened in the Phase II clinical program of IPH2201 - program rollout on track Trial conducted in the United States with leading investigator at OSU Innate Pharma SA (the “Company” -...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its fifth assessment of the EffiKIR study and...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co...

The Paoli Calmettes Institute (IPC), a private not-for-profit comprehensive cancer center in Marseille, France, has initiated a collaboration with Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics...